FDA Warns New Jersey Drugmaker Over GMP Violations

Drug Industry Daily
A A
The FDA warned Raritan Pharmaceuticals for violating GMP standards, noting the firm failed to properly test its products, which are meant for vulnerable populations, or to maintain good quality control practices.

To View This Article:

Login

Subscribe To Drug Industry Daily